Nasdaq GlobeNewswire

GW Pharmaceuticals presents latest cannabidiol oral solution (CBD) data at the 13th European Congress of Epileptology

Del

VIENNA, Austria, Aug. 28, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the development and commercialization of cannabinoid prescription medicines, presents a variety of data on cannabidiol oral solution (CBD) at the 13th Annual European Congress of Epileptology (ECE), taking place in Vienna, Austria from 26-30 August 2018.

The studies provide additional insight into the safety and efficacy of GW’s CBD oral solution in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome, two rare and severe forms of childhood-onset epilepsy that are highly treatment-resistant1 ,2. In addition, data related to the pharmacology of CBD, and its antiseizure properties, will provide additional understanding of CBD’s role in the management of such diseases. A marketing authorization application for GW’s CBD oral solution is currently under review by the European Medicines Agency (EMA).

“GW is proud to be presenting a wealth of data on its CBD oral solution to the epilepsy community. Our comprehensive pre-clinical and clinical programs provide an understanding of the way in which CBD exhibits anti-seizure effects and further supports its efficacy and tolerability profile in patients living with two of the most difficult-to-treat forms of epilepsy,” stated Justin Gover, GW’s Chief Executive Officer. “There is still a huge unmet medical need for effective medicines that help people suffering from severe forms of treatment resistant epilepsy, and we believe that our CBD oral solution may present an important new therapeutic option in the future.”

CBD data highlights:
Highlights include the presentation of pooled efficacy and safety data from two phase III randomized placebo-controlled trials of CBD in LGS, Phase 1 drug-drug interaction data on the co-administration of CBD and clobazam, and the potential role of GPR55 and the TRPV1 receptor-dependent interaction in the anti-epileptic properties of CBD.

The full list of GW titles presented are as follows:

  • Cannabidiol (CBD) Significantly Reduces Drop Seizure Frequency in Lennox-Gastaut Syndrome (LGS): Pooled Efficacy and Safety Results from 2 Randomized, Controlled Trials
  • Bidirectional Drug-drug Interaction with coadministration of Cannabidiol and Clobazam in a Phase 1 Healthy Volunteer Trial
  • Maintained Safety and Efficacy of Cannabidiol (CBD) in a Long-Term Open-Label Trial in Patients with Lennox-Gastaut Syndrome (LGS) (GWPCARE 5)
  • Exposure-Response Analysis of Cannabidiol Oral Solution for the Treatment of Lennox–Gastaut Syndrome
  • A Phase 2 Trial to Explore the Potential for a Pharmacokinetic Drug-drug Interaction with Valproate when in Combination with Cannabidiol in Adult Epilepsy Patients (late breaking abstract)
  • Antiseizure properties of CBD are attenuated in the absence of TRPV1 receptors
  • A role of GPR55 in the anti-epileptic properties of cannabidiol
  • Maintenance of Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome (DS): Results of the Open-Label Extension (OLE) Trial (GWPCARE 5)
  • Bidirectional Drug-drug Interactions with Co-administration of Cannabidiol and Stiripentol or Valproate in a Phase 1 Healthy Volunteer Trial

About GW Pharmaceuticals plc (NASDAQ: GWPH)

Founded in 1998, GW is a world leader in the development and commercialization of cannabinoid prescription medicines. The Company’s lead investigational medicine, cannabidiol oral solution (Epidiolex® in the US), received U.S. FDA approval in June 2018 and is under review by European regulators. Previously, GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (delta-9-tetrahydrocannibinol and cannabidiol) in Europe and is now advancing plans to develop this medicine in the US. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in development for epilepsy, autism, glioblastoma, and schizophrenia. For further information, please visit our global corporate website at www.gwpharm.com.

Forward-looking statements

This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of GW products commercially available and in development, the clinical benefits of Epidiolex® (cannabidiol) oral solution and the safety profile and commercial potential of Epidiolex®. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of GW’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, and the acceptance of Sativex®, Epidiolex® and other products by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in GW can be found in GW’s filings with the U.S. Securities and Exchange Commission, including the most recent Form 20-F filed on 4 December 2017. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Enquiries:

GW Pharmaceuticals plc  
Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570
   
EU Media Enquiries:  
FTI Consulting +44 (0)20 3727 1000

1 LGS Foundation. About Lennox-Gastaut Syndrome. Available at http://www.lgsfoundation.org/aboutlgs. Accessed May 7, 2018.

2 Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011;52(Suppl. 2):3–9.

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Province Brands of Canada Announces Proposed Reverse Takeover of Colson Capital Corporation25.9.2018 00:56Pressemelding

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. CALGARY, Alberta, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Colson Capital Corp. (“Colson” or the “Corporation”) (TSXV: COLS.P) and Honest Inc., dba Province Brands of Canada (“Province Brands”), are pleased to announce that they have entered into an amended and restated arrangement agreement dated September 17, 2018 (the “Arrangement Agreement”) in respect of their proposed business combination transaction (the “Proposed Transaction”) which was previously announced in the news release of the Corporation dated June 5, 2018. The Proposed Transaction is expected to constitute Colson’s Qualifying Transaction under Policy 2.4 – Capital Pool Companies (“Policy 2.4”) of the TSX Venture Exchange (the “Exchange” or “TSXV”), subject to the TSXV’s approval. It is expected that the Resulting Issuer (as defined below) wil

Northland Power Opens Offshore Wind Operations Hub in Germany24.9.2018 23:30Pressemelding

New organizations support Northland’s expanded capabilities TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) today announced the opening of its offshore wind operations hub in Germany. The hub represents an expansion of Northland’s focus on offshore wind operations. Initial activities are focused on achieving synergies across the 332 MW Nordsee One wind farm, which commenced commercial operations in 2017, and the 269 MW Deutsche Bucht project, which is currently in construction. The team will also support Northland’s global project development work. Operations and maintenance activities, including remote monitoring and control of the wind turbines and substations, have been centralized in a port-side facility in the village of Norddeich. Commercial and engineering activities are being managed from a new office in the Hamburg area. “I’m pleased to welcome the Northland team to their new headquarters,” noted Troy Patton, Chief Ope

Concord Technologies Unveils NEXTSTEP—AI-driven, Cloud-based Platform that Simplifies Patient Data Capture and Document Workflows24.9.2018 23:12Pressemelding

SEATTLE, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Concord Technologies, a leading provider of cloud fax services and document process automation solutions, today launched NEXTSTEP, a new, AI-driven, cloud-based platform optimized for healthcare providers to reduce the effort required to capture, access and integrate patient health information from paper and digital documents. Concord has optimized NEXTSTEP for healthcare providers struggling to digitize document-intensive clinical workflows, though its core features apply across all highly-regulated industries. Unlike conventional systems, NEXTSTEP is pre-trained to identify, classify and extract specific, field-level data, so it saves providers the cost and effort to “teach” the system what to look for. It also extends automated document classification and routing with the ability to coordinate document handling even with frequently-changing clinical processes. “We estimate a sizable market of providers who are being underserved by conventi

The Connecticut Institute for Refugees and Immigrants honors Ethan Allen’s Farooq Kathwari24.9.2018 23:00Pressemelding

DANBURY, Conn., Sept. 24, 2018 (GLOBE NEWSWIRE) -- The Connecticut Institute for Refugees and Immigrants (CIRI) honored Farooq Kathwari, Chairman, President and CEO of Danbury-based Ethan Allen Interiors Inc., with its Legacy Award at a gala dinner in Westport, CT., on September 23. He was chosen for this honor in recognition of his commitment to humanitarian causes, to justice and human dignity, and to the plight of displaced people across the world. Mr. Kathwari has served in numerous capacities at many nonprofit organizations; among them, he is currently a member of the Board of Overseers of the International Rescue Committee, and a chairman emeritus of Refugees International. The gala commemorated CIRI's 100 years as the state’s leading champion for refugees, immigrants, survivors of torture, and survivors of human trafficking. Founded in 1918 as the International Institute of Connecticut (IICONN), CIRI remains the state’s preeminent provider of advocacy and high-impact services th

Constellation Brands Elects Jennifer M. Daniels of Colgate-Palmolive Company to its Board of Directors24.9.2018 22:07Pressemelding

VICTOR, N.Y., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today the election of Jennifer M. Daniels, chief legal officer and secretary of Colgate-Palmolive Company, to serve as a member of its board of directors, effective as of the close of business on September 20, 2018. This election increases the size of Constellation’s board from 11 to 12 members. “We are pleased to welcome Jennifer to our board of directors,” said Constellation’s Chairman of the Board Richard Sands. “Jennifer brings extensive experience in consumer product goods, mergers and acquisitions, regulatory compliance and corporate governance that will serve as tremendous assets to our board at a very exciting time as our company explores new avenues of growth, while continuing to build momentum for our high-performing beverage alcohol business.” Since November 2014, Daniels has served as chief legal officer and secretary of Colgate-Pa

World Conference on Lung Cancer Monday Press Conference: Clinical Research Results and Gender Differences in Lung Cancer Survival24.9.2018 20:26Pressemelding

TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- At today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC), conference co-president Dr. Andrea Bezjak, M.D., FRCPC, MSc, professor in the Departments of Radiation Oncology and Health Policy, Management and Evaluation at the University of Toronto and staff radiation oncologist at Princess Margaret Cancer Centre, summarized the wide-ranging study topics presented in today’s conference, from significant clinical research findings to gender differences in lung cancer survival. IMpower132 study shows atezolizumab in combination with carboplatin and pemetrexed improves survival in Stage IV non-squamous NSCLC Recent findings from the IMpower132 study, presented by Vassiliki A. Papadimitrakopoulou, M.D., chief of the Section of Thoracic Medical Oncology at MD Anderson Cancer Center, demonstrate that the use of atezolizumab in combination with carboplatin as first-l

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom